Login to Your Account

Astrazeneca, Shenzhen University forge ties for homegrown innovation

By Shannon Ellis
Staff Writer

Wednesday, April 2, 2014

SHANGHAI – Astrazeneca plc, of London, has invested continuously in China’s R&D capabilities over the past seven years and shows no signs of letting up. The latest deal with the newly minted Nephrology and Urology Center, part of the Shenzhen University Health Science Center, will focus on preclinical research for diabetic nephropathy, the damage done to kidneys in late-stage diabetes.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription